Priser
Platform
Blog
Om os
Download
301239
Bright Eye Hospital Group Co
Shenzhen Stock Exchange
0

Om

Chengdu Bright Eye Hospital Co., Ltd. operates within the healthcare sector as a provider of specialized medical services primarily focusing on ophthalmology. The company's main purpose is to deliver comprehensive diagnostic, therapeutic, and surgical eye care services. Located in Chengdu, China, it caters to a broad demographic, from children to the elderly, aiming to improve vision and prevent blindness through advanced medical procedures and technologies. Notable for its state-of-the-art facilities and a team of skilled ophthalmologists, Chengdu Bright Eye Hospital emphasizes both preventive and corrective eye care. Its role is significant in the healthcare market by addressing the increasing demand for specialized eye care owing to changes in lifestyle and demographic shifts towards an aging population. Through its services, the company contributes to enhancing the quality of life and productivity of its patients, playing a crucial role in the local healthcare infrastructure.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I BRIGHT EYE HOSPITAL GROUP CO MED ENDAVU: Køb Bright Eye Hospital Group Co ($301239) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Bright Eye Hospital Group Co, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Information

Ticker301239
Land
Kina
Antal medarbejdere5.121
Hjemmesidepuruieyes.com
SektorSundhed
IndustriMedicinske plejefaciliteter

Udbytter

0,4CNH
'24
Ex-udbytte-dato22. jul. 2024
Udbytteafkast0%

Analytikerskøn

Baseret på 1 analytiker

Stærkt købKøbHoldSælgStærkt sælg
0%100%0%0%0%